Ashraf Hanna

Ashraf Hanna is the Chief Executive Officer at Genalyte.

Ashraf joined Genalyte as Chief Executive Officer from Verily, an Alphabet company, where he was Chief Operating Officer. Among other activities, he helped lead the company to obtain its first 510k approval and expand Covid testing sites during the pandemic. Prior to Verily, Ashraf was the CEO at ORIC Pharmaceuticals, a company focused on developing drugs for resistant cancers. Ashraf led the company from concept through preclinical and the beginning of Phase 1 clinical trials. ORIC had an IPO at approximately $1B valuation while still in Phase 1. Ashraf spent over a decade at Genentech as Vice President and head of Alliance Management, Portfolio Prioritization, and head of Commercial and Medical Affairs Finance. He started his work career at McKinsey and Company.

Ashraf has a PhD in Physics from Harvard, and an M.D. from the University of Massachusetts and studied Physics and Economics as an undergraduate at the University of Chicago.